Maravai LifeSciences Holdings, Inc. (MRVI)
Nasdaq · Healthcare · Biotechnology
$8.52+7.85%as of Oct 6, 2026, 7:35 AM ET
- Market cap
- $3.2B
- 52-week range
- $2.55 – $9.42
- 52-week change
- +138.67%
- EPS (trailing)
- −$0.53
- Analyst rating
- 1.9 Buy
- Next earnings
- Nov 5, 2026
Fiscal year to Dec 2025
- Revenue
- $186M (−28.34%)
- Net income
- −$131M
- Operating margin
- −115.9%
- Diluted EPS
- −$0.90
- Free cash flow
- −$70.7M
From the company’s annual report on SEC EDGAR.
About Maravai LifeSciences Holdings, Inc.
Maravai LifeSciences Holdings, Inc., a life sciences company, provides products that enable the development of drug therapies, vaccines, drug therapies, cell and gene therapies, and diagnostics North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin and Central America. It operates through two segments: TRILINK and CYGNUS. The TRILINK segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, and oligonucleotide therapy, as well as molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, CleanCap capping technology-based oligonucleotide building blocks, and custom enzyme development and manufacturing; and research products for labeling and detecting proteins in cells and tissue samples. The CYGNUS segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody and assay development services.
Headquarters: San Diego, United States · 415 employees · maravai.com